

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Keymed Biosciences Inc.
康諾亞生物醫藥科技有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2162)

INSIDE INFORMATION

PROPOSED ISSUE OF RMB SHARES AND LISTING ON THE SCI-TECH BOARD OF THE SHANGHAI STOCK EXCHANGE

This announcement is made by Keymed Biosciences Inc. (the “**Company**”) pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The Company is pleased to announce that, on August 19, 2026, the board of directors of the Company (the “**Board**”) resolved that the Company proposes to issue ordinary shares (the “**Proposed Issue of RMB Shares**”) to be listed and traded in Renminbi (“**RMB**”) on the Science and Technology Innovation Board of the Shanghai Stock Exchange (the “**Sci-Tech Board**”). The Proposed Issue of RMB Shares is conditional upon and subject to, among other things, market conditions, further approvals of the Board, the approval of the shareholders at a general meeting of the Company and the necessary regulatory approval(s).

As of the date of this announcement, except for the preliminary proposal for the Proposed Issue of RMB Shares and the information otherwise disclosed herein, the Board does not have any other plans in relation to the Proposed Issue of RMB Shares, and has not made any application to the relevant regulatory authorities in respect of the Proposed Issue of RMB Shares.

Shareholders and potential investors should note that the preliminary proposal for the Proposed Issue of RMB Shares approved by the Board may be subject to change. Any concrete plan for the Proposed Issue of RMB Shares, if made by the Company, and the expected timing of the Proposed Issue of RMB Shares, will be subject to, among others, further approval of the Board, the approval of the shareholders at a general meeting of the Company, and the necessary regulatory approval(s). Accordingly, the Proposed Issue of RMB Shares may or may not proceed. Shareholders and potential investors of the Company should be aware that there is no assurance as to whether or when the Proposed Issue of RMB Shares will materialize, and are therefore advised to exercise caution when dealing in the share(s) of the Company.

Further filing(s) and announcement(s) on any material updates and progress in respect of the Proposed Issue of RMB Shares will be made by the Company in accordance with the Listing Rules and other applicable laws and regulations as and when appropriate. This announcement is for information purposes only and does not constitute any invitation or offer to acquire, purchase or subscribe for the share(s) of the Company.

By order of the Board
Keymed Biosciences Inc.
Dr. Bo CHEN
Chairman

Hong Kong, August 19, 2026

As at the date of this announcement, the Board of Directors of the Company comprises Dr. Bo CHEN, Dr. Changyu WANG and Dr. Gang XU as executive Directors; Mr. Qi CHEN, Dr. Min Chuan WANG and Mr. Yilun LIU as non-executive Directors; Prof. Xiao-Fan WANG, Prof. Yang KE and Mr. Cheuk Kin Stephen LAW as independent non-executive Directors.